DNae. The first true point-of-need Next-Generation Sequencing company.
Our mission is to bring dramatic, life-changing improvements to healthcare and beyond with fast, simple and scientifically sound products. To this end, we apply the best scientific skills and energy to build an evolving and innovative suite of electronic microchip-based solutions that delivers faster, simpler and more cost-effective DNA analysis.
Regius Professor Chris Toumazou FRS, FREng, FMedSci founded the company in 2003, as a spin-out from Imperial College London, having invented a way of detecting protons released during DNA synthesis to enable DNA sequence detection using a standard silicon-chip based transistor. This optics-free, label-free method shifted DNA sequencing from specialized, expensive genome centres into the mainstream of local labs and primary care clinics.
Since its foundation, our company has grown to encompass the vast range of disciplines required to build molecular interfaces and assays on a semiconductor platform. Our core competencies in electronic engineering, molecular biology, fluidics and chemistry make us a force to be reckoned with. A force for good.
Headquartered in London, UK, and operating from Washington, DC, our company expanded operations further in 2015 with a clinical diagnostic development site in San Diego, CA.
DNae. The first true point-of-need Next Generation Sequencing company.
Our mission is to bring dramatic, life-changing improvements to healthcare and beyond with fast, simple and scientifically sound products. To this end, we apply the best scientific skills and energy to build an evolving and innovative suite of electronic microchip-based solutions that delivers faster, simpler and more cost-effective DNA analysis.
Regius Professor Chris Toumazou FRS, FREng, FMedSci founded the company in 2003, as a spin-out from Imperial College, London, having invented a way of detecting protons released during DNA synthesis to enable DNA sequence detection using a standard silicon-chip based transistor. This optics-free, label-free method shifted DNA sequencing from specialized, expensive genome centres into the mainstream of local labs and primary care clinics.
Since its foundation, our company has grown to encompass the vast range of disciplines required to build molecular interfaces and assays on a semiconductor platform. Our core competencies in electronic engineering, molecular biology, fluidics and chemistry make us a force to be reckoned with. A force for good.
Headquartered in London, UK, and operating from Washington, DC, our company expanded operations further in 2015 with a clinical diagnostic development site in San Diego, CA.
